<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tinidazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00911</strong>&#160; (APRD01260)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00911/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00911/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00911.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00911.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00911.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00911.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00911.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00911">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Fasigyn</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tindamax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tindazole</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antiprotozoal-agents">Antiprotozoal Agents</a></li>
<li><a href="/mesh/anti-infective-agents">Anti-Infective Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>19387-91-8</td></tr><tr><th>Weight</th><td>Average: 247.272<br>Monoisotopic: 247.062676609</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S</td></tr><tr><th>InChI Key</th><td>HJLSLZFTEKNLFI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[2-(ethanesulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Imidazoles</td></tr><tr><th>Direct parent</th><td>Nitroimidazoles</td></tr><tr><th>Alternative parents</th><td>Trisubstituted Imidazoles; N-substituted Imidazoles; Sulfones; Sulfoxides; Nitro Compounds; Nitronic Acids; Organic Oxoazanium Compounds; Polyamines</td></tr><tr><th>Substituents</th><td>n-substituted imidazole; sulfone; sulfonyl; nitronic acid; nitro compound; sulfoxide; organic oxoazanium; polyamine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the nitroimidazoles. These are compounds containing an imidazole ring which bears a nitro group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of trichomoniasis caused by <i>T. vaginalis</i> in both female and male patients. Also for the treatment of giardiasis caused by <i>G. duodenalis</i> in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by <i>E. histolytica</i> in both adults and pediatric patients older than three years of age.</td></tr><tr><th>Pharmacodynamics</th><td>Tinidazole is a synthetic antiprotozoal agent. Tinidazole demonstrates activity both in vitro and in clinical infections against the following protozoa: <i>Trichomonas vaginalis</i>, <i>Giardia duodenalis</i> (also termed <i>G. lamblia</i>), and <i>Entamoeba histolytica</i>. Tinidazole does not appear to have activity against most strains of vaginal lactobacilli.</td></tr><tr><th>Mechanism of action</th><td>Tinidazole is a prodrug and antiprotozoal agent. The nitro group of tinidazole is reduced in <i>Trichomonas</i> by a ferredoxin-mediated electron transport system. The free nitro radical generated as a result of this reduction is believed to be responsible for the antiprotozoal activity. It is suggested that the toxic free radicals covalently bind to DNA, causing DNA damage and leading to cell death. The mechanism by which tinidazole exhibits activity against <i>Giardia</i> and <i>Entamoeba</i> species is not known, though it is probably similar.</td></tr><tr><th>Absorption</th><td>Rapidly and completely absorbed under fasting conditions. Administration with food results in a delay in T<sub>max</sub> of approximately 2 hours and a decline in C<sub>max</sub> of approximately 10% and an AUC of 901.6 &#177; 126.5 mcg hr/mL.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>50 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Plasma protein binding of tinidazole is 12%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, mainly via CYP3A4. Tinidazole, like metronidazole, is significantly metabolized in humans prior to excretion. Tinidazole is partly metabolized by oxidation, hydroxylation and conjugation. Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite.</p></td></tr><tr><th>Route of elimination</th><td>Tinidazole crosses the placental barrier and is secreted in breast milk. Tinidazole is excreted by the liver and the kidneys.
Tinidazole is excreted in the urine mainly as unchanged drug (approximately 20-25% of the administered dose).
Approximately 12% of the drug is excreted in the feces.</td></tr><tr><th>Half life</th><td>Elimination half-life is 13.2 &#177; 1.4 hours. Plasma half-life is 12 to 14 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>There are no reported overdoses with tinidazole in humans. In acute studies with mice and rats, the LD 50 for mice was generally &gt; 3,600 mg/kg for oral administration and was &gt; 2,300 mg/kg for intraperitoneal administration. In rats, the LD 50 was &gt; 2,000 mg/kg for both oral and intraperitoneal administration.</td></tr><tr><th>Affected organisms</th><td><ul><li>Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.975</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9308</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6003</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6257</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7815</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9706</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8178</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7946</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5149</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.876</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7518</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9106
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5986
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7608
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1458 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5582
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5554
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Mission pharmacal co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.biocomppharma.com">BioComp Pharma</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.missionpharmacal.com">Mission Pharmacal</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.presuttilabs.com">Presutti Laboratories Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>